Blockchain Registration Transaction Record

Telomir-Zn Shows Promise in Osteosarcoma; TNBC Program Advances

Telomir Pharmaceuticals reports Telomir-Zn inhibits osteosarcoma growth in human and canine models. TNBC program advances to Phase 1/2 under FDA-cleared IND.

<p>This news matters because it highlights a potential new therapeutic avenue for osteosarcoma, a rare and aggressive bone cancer that primarily affects children and young adults. Current treatment options for osteosarcoma are limited, often involving surgery and chemotherapy with significant side effects. The finding that Telomir-Zn inhibits growth in both human and canine osteosarcoma cell lines at low concentrations suggests a possible dual-benefit approach: developing a veterinary treatment for dogs with naturally occurring osteosarcoma while simultaneously gathering translational data that could accelerate human clinical trials. This comparative oncology strategy is increasingly recognized as a valuable tool to de-risk oncology drug development. Moreover, Telomir’s ongoing Phase 1/2 trial in triple-negative breast cancer—a particularly difficult-to-treat form of breast cancer—demonstrates the company’s broader commitment to addressing unmet needs in oncology. For investors, these developments could signal multiple shots on goal within a single pipeline, potentially increasing the chances of clinical and commercial success.</p>